H1975, an EGFR-driven human lung cancer cell line, carries both a primary mutation in EGFR (L858R) and a second site mutation in EGFR (T790M) that confers resistance to small molecule EGFR TKIs such as erlotinib. This evidence concerns the gene EGFR and lung cancer.